ZVSA news & sentiment — ZyVersa Therapeutics, Inc.

SEP 10·GlobeNewswireLow

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

Inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complications.

SEP 3·Benzinga

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression - ZyVersa Therapeutics ( OTC:ZVSA )

By removing excess renal lipids, VAR 200 is expected to attenuate other pathways that are key contributors to renal disease - inflammation, fibrosis, oxidative and endoplasmic reticulum stress. This is based on a VAR 200 preclinical study in Alport syndrome [Mitrofanova.

SEP 3·GlobeNewswire

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation.

$ZVSA

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression - ZyVersa Therapeutics ( OTC:ZVSA )

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

News on $ZVSA